SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin informs about press release

26 Nov 2018 Evaluate

Lupin has informed about submission of a Press Release as regards receipt of USFDA approval for Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg, and 75 mg, to market a generic version of SpecGx LLC’s Anafranil Capsules, 25 mg, 50 mg, and 75 mg. It is considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2271.80 26.15 (1.16%)
12-May-2026 11:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1877.50
Dr. Reddys Lab 1286.00
Cipla 1306.60
Zydus Lifesciences 943.40
Lupin 2271.80
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×